Likewise, glucagon-like peptide-1 receptor agonists (GLP1-RAs), approved for type 2 diabetes and obesity, achieve weight loss ≥ 5% from baseline in 60%, 85%, and 90% of patients treated with liraglutide, semaglutide, and tirzepatide, respectively. Here, GLP1R is linked to type 2 diabetes mellitus.